Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy PTC Therapeutics stock | $39.27
Learn how to easily invest in PTC Therapeutics stock.
PTC Therapeutics, Inc is a biotechnology business based in the US. PTC Therapeutics shares (PTCT) are listed on the NASDAQ and all prices are listed in US Dollars. PTC Therapeutics employs 959 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in PTC Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PTCT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
PTC Therapeutics stock price (NASDAQ: PTCT)Use our graph to track the performance of PTCT stocks over time.
PTC Therapeutics shares at a glance
|Latest market close||$39.27|
|52-week range||$37.12 - $70.82|
|50-day moving average||$42.99|
|200-day moving average||$49.29|
|Wall St. target price||$57.22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.10|
Buy PTC Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy PTC Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
PTC Therapeutics price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-10.26%|
|3 months (2021-04-30)||-4.71%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Is PTC Therapeutics under- or over-valued?
Valuing PTC Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PTC Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PTC Therapeutics's PEG ratio
PTC Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PTC Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PTC Therapeutics financials
|Revenue TTM||$430.4 million|
|Gross profit TTM||$-62,219,000|
|Return on assets TTM||-11.57%|
|Return on equity TTM||-110.58%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
Shorting PTC Therapeutics shares
There are currently 4.8 million PTC Therapeutics shares held short by investors – that's known as PTC Therapeutics's "short interest". This figure is 0.3% up from 4.8 million last month.
There are a few different ways that this level of interest in shorting PTC Therapeutics shares can be evaluated.
PTC Therapeutics's "short interest ratio" (SIR)
PTC Therapeutics's "short interest ratio" (SIR) is the quantity of PTC Therapeutics shares currently shorted divided by the average quantity of PTC Therapeutics shares traded daily (recently around 395506.06557377). PTC Therapeutics's SIR currently stands at 12.2. In other words for every 100,000 PTC Therapeutics shares traded daily on the market, roughly 12200 shares are currently held short.
However PTC Therapeutics's short interest can also be evaluated against the total number of PTC Therapeutics shares, or, against the total number of tradable PTC Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PTC Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 PTC Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0796% of the tradable shares (for every 100,000 tradable PTC Therapeutics shares, roughly 80 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against PTC Therapeutics.
Find out more about how you can short PTC Therapeutics stock.
PTC Therapeutics share dividends
We're not expecting PTC Therapeutics to pay a dividend over the next 12 months.
PTC Therapeutics share price volatility
Over the last 12 months, PTC Therapeutics's shares have ranged in value from as little as $37.122 up to $70.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PTC Therapeutics's is 0.981. This would suggest that PTC Therapeutics's shares are less volatile than average (for this exchange).
PTC Therapeutics overview
PTC Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F.
Stocks similar to PTC Therapeutics
PTC Therapeutics in the news
PTC Therapeutics: Q2 Earnings Snapshot
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
Frequently asked questionsWhat percentage of PTC Therapeutics is owned by insiders or institutions?
Currently 2.938% of PTC Therapeutics shares are held by insiders and 106.345% by institutions. How many people work for PTC Therapeutics?
Latest data suggests 959 work at PTC Therapeutics. When does the fiscal year end for PTC Therapeutics?
PTC Therapeutics's fiscal year ends in December. Where is PTC Therapeutics based?
PTC Therapeutics's address is: 100 Corporate Court, South Plainfield, NJ, United States, 07080 What is PTC Therapeutics's ISIN number?
PTC Therapeutics's international securities identification number is: US69366J2006 What is PTC Therapeutics's CUSIP number?
PTC Therapeutics's Committee on Uniform Securities Identification Procedures number is: 69366J200
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert